Article Type
Changed
Fri, 01/18/2019 - 16:50

 

DTaP5-inactivated polio vaccine (IPV)-hepatitis B (HB)-Haemophilus influenzae type b (Hib) used in a series with DTaP5-IPV-Hib showed strong immune responses against all the hexavalent antigens, said Federico Martinón-Torres, MD, of Hospital Clinico Universitario de Santiago de Compostela, Spain, and his associates.

DTaP5-IPV-HB-Hib combination vaccine has a five-antigen pertussis component and contains polyribosylribitol phosphate–Neisseria meningitidis serogroup B outer membrane protein [PRP-OMP] Hib conjugate, while DTaP5-IPV-Hib contains polyribosylribitol phosphate-tetanus toxoid (PRP-T) Hib conjugate.

copyright DesignPics/Thinkstock
“The purpose of the current study was to assess the immunogenicity of a mixed primary series schedule of DTaP5-HB-IPV-Hib at 2 and 6 months of age and DTaP5-IPV-Hib at 4 months of age, to evaluate the immunogenicity of a concomitantly administered MCC [meningococcal serogroup C] ... and to describe the safety profile of the mixed schedule,” the investigators said.

The phase III, open-label, single-arm study in 12 Spanish hospitals and health centers included 384 infants who had received only one dose of monovalent hepatitis B vaccine within 3 days of birth prior to starting the study. They then received the hexa/penta/hexa combo vaccines concomitantly with the MCC vaccine. The response rate was 100% against Hib and 98.9% against hepatitis B.

Also, a “robust immune response was induced against all other disease antigens,” said Dr. Martinón-Torres and his colleagues. Coadministration of the combo vaccines with the meningococcal vaccine likewise did not appear to compromise immunogenicity of any of the vaccine antigens.

Use of the hexa/penta/hexa combo vaccine series was mostly safe and well tolerated, the researchers said.

Read more in the journal Vaccine (2017 Jun 17;35[30];3764-72).

Publications
Topics
Sections

 

DTaP5-inactivated polio vaccine (IPV)-hepatitis B (HB)-Haemophilus influenzae type b (Hib) used in a series with DTaP5-IPV-Hib showed strong immune responses against all the hexavalent antigens, said Federico Martinón-Torres, MD, of Hospital Clinico Universitario de Santiago de Compostela, Spain, and his associates.

DTaP5-IPV-HB-Hib combination vaccine has a five-antigen pertussis component and contains polyribosylribitol phosphate–Neisseria meningitidis serogroup B outer membrane protein [PRP-OMP] Hib conjugate, while DTaP5-IPV-Hib contains polyribosylribitol phosphate-tetanus toxoid (PRP-T) Hib conjugate.

copyright DesignPics/Thinkstock
“The purpose of the current study was to assess the immunogenicity of a mixed primary series schedule of DTaP5-HB-IPV-Hib at 2 and 6 months of age and DTaP5-IPV-Hib at 4 months of age, to evaluate the immunogenicity of a concomitantly administered MCC [meningococcal serogroup C] ... and to describe the safety profile of the mixed schedule,” the investigators said.

The phase III, open-label, single-arm study in 12 Spanish hospitals and health centers included 384 infants who had received only one dose of monovalent hepatitis B vaccine within 3 days of birth prior to starting the study. They then received the hexa/penta/hexa combo vaccines concomitantly with the MCC vaccine. The response rate was 100% against Hib and 98.9% against hepatitis B.

Also, a “robust immune response was induced against all other disease antigens,” said Dr. Martinón-Torres and his colleagues. Coadministration of the combo vaccines with the meningococcal vaccine likewise did not appear to compromise immunogenicity of any of the vaccine antigens.

Use of the hexa/penta/hexa combo vaccine series was mostly safe and well tolerated, the researchers said.

Read more in the journal Vaccine (2017 Jun 17;35[30];3764-72).

 

DTaP5-inactivated polio vaccine (IPV)-hepatitis B (HB)-Haemophilus influenzae type b (Hib) used in a series with DTaP5-IPV-Hib showed strong immune responses against all the hexavalent antigens, said Federico Martinón-Torres, MD, of Hospital Clinico Universitario de Santiago de Compostela, Spain, and his associates.

DTaP5-IPV-HB-Hib combination vaccine has a five-antigen pertussis component and contains polyribosylribitol phosphate–Neisseria meningitidis serogroup B outer membrane protein [PRP-OMP] Hib conjugate, while DTaP5-IPV-Hib contains polyribosylribitol phosphate-tetanus toxoid (PRP-T) Hib conjugate.

copyright DesignPics/Thinkstock
“The purpose of the current study was to assess the immunogenicity of a mixed primary series schedule of DTaP5-HB-IPV-Hib at 2 and 6 months of age and DTaP5-IPV-Hib at 4 months of age, to evaluate the immunogenicity of a concomitantly administered MCC [meningococcal serogroup C] ... and to describe the safety profile of the mixed schedule,” the investigators said.

The phase III, open-label, single-arm study in 12 Spanish hospitals and health centers included 384 infants who had received only one dose of monovalent hepatitis B vaccine within 3 days of birth prior to starting the study. They then received the hexa/penta/hexa combo vaccines concomitantly with the MCC vaccine. The response rate was 100% against Hib and 98.9% against hepatitis B.

Also, a “robust immune response was induced against all other disease antigens,” said Dr. Martinón-Torres and his colleagues. Coadministration of the combo vaccines with the meningococcal vaccine likewise did not appear to compromise immunogenicity of any of the vaccine antigens.

Use of the hexa/penta/hexa combo vaccine series was mostly safe and well tolerated, the researchers said.

Read more in the journal Vaccine (2017 Jun 17;35[30];3764-72).

Publications
Publications
Topics
Article Type
Sections
Article Source

FROM VACCINE

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME